drugset / Trial / NCT02319603

To Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats

NCT02319603 ↗

Phase 4 Unknown 288 enrolled Beijing Bozhiyin T&S Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, two dose group, parallel-control multi-center, post-marketing clinical trial,to evaluate the efficacy and safety of Wenxin keli in treating atrial premature beats by different dose,to provide a scientific basis for rational clinical use of drug.

Timeline

Start
2015-01
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator WenXin keli Unknown 5 g Oral
Comparator WenXin keli Unknown 10 g Oral